Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Sex: All

Ages: 21 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 91

Sponsor: VivaVision Biotech, Inc

Summary

This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification

Eligibility Criteria

Inclusion Criteria: * ≥21 years of age and in good general health at Visit 1 (Screening) * Willing and able to provide informed consent and provide relevant privacy authorization(s) * Willing and able to comply with study requirements and visit schedule * Clear ocular media (other than cataract) in the study eye * Planning to undergo routine unilateral cataract surgery via phacoemulsification extraction and implantation of an intraocular lens. Exclusion Criteria: * Any ocular pain at Visit 1 (Screening) * Recent use of corticosteroids or oral non-steroidal anti-inflammatory drugs

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06164743). StuddyBuddy aggregates publicly available trial information.